Foxo Technologies Signs Deal to Purchase Vector Biosource
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Sep 11 2025
0mins
Acquisition Details: FOXO Technologies has signed a stock purchase agreement to acquire Vector Biosource, a provider of information, data, and biospecimens for the biotechnology and pharmaceutical industries, for a total expected purchase price of $500,000 in cash, shares, and warrants.
Financial Expectations: Vector generated approximately $225,000 in net revenues in Q2 2025 and is anticipated to experience significant growth post-acquisition, with FOXO also committing to fund up to $1.2 million for Vector's growth initiatives.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
